PE20180930A1 - Composiciones y metodos para la vigilancia activa del cancer de prostata - Google Patents

Composiciones y metodos para la vigilancia activa del cancer de prostata

Info

Publication number
PE20180930A1
PE20180930A1 PE2018000345A PE2018000345A PE20180930A1 PE 20180930 A1 PE20180930 A1 PE 20180930A1 PE 2018000345 A PE2018000345 A PE 2018000345A PE 2018000345 A PE2018000345 A PE 2018000345A PE 20180930 A1 PE20180930 A1 PE 20180930A1
Authority
PE
Peru
Prior art keywords
prostate cancer
prostate
markers
probability
compositions
Prior art date
Application number
PE2018000345A
Other languages
English (en)
Inventor
Yan Dong
Andrew J Vickers
Daniel Sjoberg
Peter T Scardino
Hans Lilja
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of PE20180930A1 publication Critical patent/PE20180930A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Algebra (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Software Systems (AREA)
  • Computing Systems (AREA)
  • Pure & Applied Mathematics (AREA)

Abstract

SE REFIERE A UN METODO PARA EVALUAR UN SUJETO PREVIAMENTE DIAGNOSTICADO CON CANCER DE PROSTATA NO AGRESIVO, EL CUAL COMPRENDE: I) SOMETER UNA MUESTRA DE SANGRE A UNO O MAS INMUNOENSAYOS QUE MIDEN LOS NIVELES DE UNO O MAS MARCADORES DE CALICREINA SELECCIONADOS DE ANTIGENO ESPECIFICO DE PROSTATA LIBRE (fPSA), ANTIGENO ESPECIFICO DE PROSTATA INTACTO (iPSA), ANTIGENO ESPECIFICO DE PROSTATA TOTAL (tPSA) Y CALICREINA 2 HUMANA (hK2); Y II) DETERMINAR LA PROBABILIDAD DE QUE UNA BIOPSIA DE TEJIDO DE PROSTATA OBTENIDA DEL SUJETO CONTENGA CANCER DE PROSTATA AGRESIVO DETECTABLE PONDERANDO UNO O MAS MARCADORES DE CALICREINA MEDIDOS Y AL MENOS UN FACTOR CLINICO. TAMBIEN SE REFIERE AL USO DE UN ORDENADOR CON UN SISTEMA Y UN ALMACENAMIENTO PARA DETERMINAR UNA PROBABILIDAD DE ACONTECIMIENTO ASOCIADO CON CANCER DE PROSTATA
PE2018000345A 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata PE20180930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154616P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
PE20180930A1 true PE20180930A1 (es) 2018-06-08

Family

ID=57198800

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000345A PE20180930A1 (es) 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata

Country Status (20)

Country Link
US (2) US20160320394A1 (es)
EP (2) EP3247387A4 (es)
JP (1) JP6873916B2 (es)
KR (1) KR102527446B1 (es)
CN (1) CN107530412A (es)
AU (1) AU2016254127B2 (es)
CA (1) CA2982262A1 (es)
CL (1) CL2017002701A1 (es)
CO (1) CO2017010808A2 (es)
DE (1) DE202016008673U1 (es)
EA (1) EA039028B1 (es)
HK (2) HK1247824A1 (es)
IL (1) IL254833B (es)
MX (1) MX2017013881A (es)
MY (1) MY197117A (es)
PE (1) PE20180930A1 (es)
SG (1) SG11201708289TA (es)
TW (1) TWI766836B (es)
UA (1) UA125745C2 (es)
WO (1) WO2016176529A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087999A1 (en) 2009-02-02 2010-08-05 Claros Diagnostics, Inc. Structures for controlling light interaction with microfluidic devices
CN108108590A (zh) 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
AU2016365824B2 (en) 2015-12-11 2022-07-21 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
WO2017116979A1 (en) 2015-12-29 2017-07-06 Opko Diagnostics, Llc Fluid collection device and related methods
WO2019221930A1 (en) * 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
CA3016967C (en) 2010-04-16 2021-08-31 Opko Diagnostics, Llc Systems and devices for analysis of samples
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
CA2871877A1 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
DK2922967T3 (en) * 2012-11-20 2018-04-16 Phadia Ab PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES
CA2891394C (en) * 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer

Also Published As

Publication number Publication date
CL2017002701A1 (es) 2018-07-06
IL254833B (en) 2021-12-01
JP6873916B2 (ja) 2021-05-19
EP3287786A2 (en) 2018-02-28
EP3247387A4 (en) 2018-09-12
CA2982262A1 (en) 2016-11-03
TW201705028A (zh) 2017-02-01
EA039028B1 (ru) 2021-11-24
EP3287786A3 (en) 2018-03-21
JP2018518661A (ja) 2018-07-12
CO2017010808A2 (es) 2018-04-19
SG11201708289TA (en) 2017-11-29
EA201792372A1 (ru) 2018-03-30
AU2016254127B2 (en) 2022-05-26
AU2016254127A1 (en) 2017-10-26
MY197117A (en) 2023-05-26
TWI766836B (zh) 2022-06-11
BR112017022391A2 (pt) 2018-07-10
WO2016176529A1 (en) 2016-11-03
IL254833A0 (en) 2017-12-31
DE202016008673U1 (de) 2019-01-22
KR20180018514A (ko) 2018-02-21
HK1247559A1 (zh) 2018-09-28
KR102527446B1 (ko) 2023-05-02
US20220399121A1 (en) 2022-12-15
UA125745C2 (uk) 2022-06-01
EP3247387A1 (en) 2017-11-29
MX2017013881A (es) 2018-03-12
US20160320394A1 (en) 2016-11-03
CN107530412A (zh) 2018-01-02
HK1247824A1 (zh) 2018-10-05

Similar Documents

Publication Publication Date Title
AR099883A1 (es) Computadora y métodos relacionados con el diagnóstico de cáncer de próstata
MX2021006560A (es) Perfilado transcriptómico para prognosis de cáncer de mama.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112013027124A2 (pt) método e sistema para analisar características de tecido
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2010005081A (es) Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
MX2022014741A (es) Metodos para detectar bordetella.
BR112017003751A2 (pt) medida e diagnóstico de ruído em ambiente urbano
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
MX2015013172A (es) Metodos para determinar el pronostico de cancer colorrectal.
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência